These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18698135)

  • 1. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria.
    Grujic D; Salido EC; Shenoy BC; Langman CB; McGrath ME; Patel RJ; Rashid A; Mandapati S; Jung CW; Margolin AL
    Am J Nephrol; 2009; 29(2):86-93. PubMed ID: 18698135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats.
    Paul E; Albert A; Ponnusamy S; Mishra SR; Vignesh AG; Sivakumar SM; Sivasamy G; Sadasivam SG
    Microbiol Res; 2018 Oct; 215():65-75. PubMed ID: 30172310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiurolithic effect of lupeol and lupeol linoleate in experimental hyperoxaluria.
    Sudhahar V; Veena CK; Varalakshmi P
    J Nat Prod; 2008 Sep; 71(9):1509-12. PubMed ID: 18717586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A polyherbal formulation attenuates hyperoxaluria-induced oxidative stress and prevents subsequent deposition of calcium oxalate crystals and renal cell injury in rat kidneys.
    Bodakhe KS; Namdeo KP; Patra KC; Machwal L; Pareta SK
    Chin J Nat Med; 2013 Sep; 11(5):466-71. PubMed ID: 24359768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counteraction of oxalate induced nitrosative stress by supplementation of l-arginine, a potent antilithic agent.
    Pragasam V; Kalaiselvi P; Sumitra K; Srinivasan S; Varalakshmi P
    Clin Chim Acta; 2005 Apr; 354(1-2):159-66. PubMed ID: 15748613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of oxalate-enriched spinach extract as an improved methodology for the induction of dietary hyperoxaluric nephrocalcinosis in experimental rats.
    Albert A; Tiwari V; Paul E; Ponnusamy S; Ganesan D; Prabhakaran R; Mariaraj Sivakumar S; Govindan Sadasivam S
    Toxicol Mech Methods; 2018 Mar; 28(3):195-204. PubMed ID: 28980857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in renal hemodynamics and urodynamics in rats with chronic hyperoxaluria and after acute oxalate infusion: role of free radicals.
    Huang HS; Ma MC; Chen J; Chen CF
    Neurourol Urodyn; 2003; 22(2):176-82. PubMed ID: 12579636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of urinary risk factors of stone formation by Salvadora persica in experimental hyperoxaluria.
    Geetha K; Manavalan R; Venkappayya D
    Methods Find Exp Clin Pharmacol; 2010 Nov; 32(9):623-9. PubMed ID: 21225013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral L-arginine supplementation ameliorates urinary risk factors and kinetic modulation of Tamm-Horsfall glycoprotein in experimental hyperoxaluric rats.
    Pragasam V; Kalaiselvi P; Sumitra K; Srinivasan S; Varalakshmi P
    Clin Chim Acta; 2005 Oct; 360(1-2):141-50. PubMed ID: 15992786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
    Verhulst A; Dehmel B; Lindner E; Akerman ME; D'Haese PC
    Urolithiasis; 2022 Apr; 50(2):119-130. PubMed ID: 35122487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL; Nakada SY
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status.
    Thamilselvan S; Menon M
    BJU Int; 2005 Jul; 96(1):117-26. PubMed ID: 15963133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.
    Hoppe B; Dittlich K; Fehrenbach H; Plum G; Beck BB
    Am J Kidney Dis; 2011 Sep; 58(3):453-5. PubMed ID: 21705122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
    Langman CB; Grujic D; Pease RM; Easter L; Nezzer J; Margolin A; Brettman L
    Am J Nephrol; 2016; 44(2):150-8. PubMed ID: 27529510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
    Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice.
    Dawson PA; Russell CS; Lee S; McLeay SC; van Dongen JM; Cowley DM; Clarke LA; Markovich D
    J Clin Invest; 2010 Mar; 120(3):706-12. PubMed ID: 20160351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats.
    Green ML; Hatch M; Freel RW
    Am J Physiol Renal Physiol; 2005 Sep; 289(3):F536-43. PubMed ID: 15855660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
    Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D
    Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.